Scientists have uncovered a potential new mechanism whereby α-synuclein pathology spreads. Like black holes, large densities of α-synuclein pull in surrounding matter. Among the victims trapped in ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Introduction Despite being arguably the second most common dementing disorder, dementia with Lewy bodies, aka DLB, remains both mysterious and understudied. On Tuesday, October 10, 2017, the Lewy Body ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

On donanemab, younger people with fewer tangles benefitted the most. On lecanemab, too, people with the fewest tangles improved most on CDR-SB. In the DIAN prevention trial, eight years of ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...